# Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

> **NCT00509041** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 46 (actual)

## Conditions studied

- Malignant Mesothelioma

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00509041
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-02
- **Final completion:** 2012-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2016-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509041, "Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00509041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*